Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Wall Street Zen

Key Points

• Supernus Pharmaceuticals has been upgraded to a "buy" rating by Wall Street Zen, moving from a previous "hold" rating in a research report issued on Saturday.
• Cantor Fitzgerald also upgraded the company, lifting its rating from "neutral" to "overweight" with a target price set at $42.00.
• Supernus Pharmaceuticals has seen recent institutional investments, with some institutions significantly increasing their stakes in the company during the first quarter of 2023.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report released on Saturday.

Separately, Cantor Fitzgerald raised Supernus Pharmaceuticals from a "neutral" rating to an "overweight" rating and set a $42.00 target price for the company in a research note on Wednesday, July 30th.

Supernus Pharmaceuticals Stock Up 11.8%

NASDAQ SUPN traded up $4.43 during trading hours on Friday, hitting $41.96. The company had a trading volume of 2,289,351 shares, compared to its average volume of 605,360. Supernus Pharmaceuticals has a fifty-two week low of $29.16 and a fifty-two week high of $43.62. The business has a fifty day simple moving average of $32.84 and a 200-day simple moving average of $33.36. The firm has a market cap of $2.35 billion, a P/E ratio of 38.03 and a beta of 0.74.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in SUPN. Raiffeisen Bank International AG acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at about $25,000. Financial Management Professionals Inc. acquired a new position in shares of Supernus Pharmaceuticals during the 1st quarter valued at about $30,000. Versant Capital Management Inc increased its holdings in shares of Supernus Pharmaceuticals by 6,931.3% during the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after acquiring an additional 1,109 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Supernus Pharmaceuticals during the 1st quarter valued at about $41,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at about $42,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.